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ABSTRACT: A potential threat to the success of new tuberculosis (TB) drugs is the development of
resistance. Using drugs in appropriate regimens, such as those recommended in the World Health
Organization (WHO) treatment guidelines, prevents the development ofresistance. We performed a
systematic review to assess the prevalence of inappropriate prescription of TB drugs for the
treatment of TB.
MEDLINE, EMBASE and other databases were searched for relevant articles in January 2011.
Observational studies published from 2000 that included TB patients receiving treatment were
selected. A treatment regimen was considered inappropriate if the regimen was not a WHO
recommended regimen.
37 studies were included. Inappropriate treatment regimens were prescribed in 67% of studies.
The percentage of patients receiving inappropriate regimens varied between 0.4% and 100%. In
19 studies the quality of treatment regimen reporting was low.
Despite the fact that assessment of inappropriate treatment was hampered by low quality of
reporting, our data indicate a reasonable amount of inappropriate prescription of TB treatment
regimens. Thus, there is a risk that new drugs will be used in inappropriate treatment regimens,
even with WHO guidelines in place, introducing the risk of resistance development. This article
highlights the need to improve implementation of the WHO treatment of TB guidelines.
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T
he currently used tuberculosis (TB) drugs
date back more than 50 yrs. Soon after
their introduction the emergence of drug
resistance was observed [1]. This led to the use of
a double-drug combination to prevent the emer-
gence of drug resistance, and later to triple-drug
combinations. Four-drug short-course regimens
were first tested in 1972 and showed positive
results [2]. A four-drug short-course regimen is
currently recommended by the World Health
Organization (WHO) [3].
Recently, 10 compounds have progressed to the
clinical development stage for the treatment of TB
[4]. These new compounds, if properly managed,
have the potential to become part of a future
r e g i m e nt h a tc o u l dg r e a t l yi m p a c to nt h eg l o b a lT B
control effort. A potential threat to the success of the
new compounds is the development of resistance
caused by inappropriate use of these drugs [5]. For
these new drugs to remain effective it is essential
that they are used in regimens that prevent the
development of resistance to the drugs. The WHO
has developed guidelines on appropriate (standar-
dised) TB treatment regimens that will cure patients
and prevent the development of resistance. The first
guidelines were published in 1993 [6], and updates
followed in 1997 [7], 2003 [8] and 2009 [3].
Implementation of global TB treatment guidelines
requires the uptake of the recommendations in
national TB treatment guidelines and the use of
national treatment guidelines by all health work-
ers. Initially, 83 (48%) out of 174 countries
reporting to the WHO did not accept the WHO-
TB control strategy [9]. 10 yrs later, most countries
were implementing the DOTS (Directly Observed
Treatment Short Course) strategy, including four-
drug short-course regimens. Although countries
have implemented the DOTS strategy, individual
healthcare workers might not be aware of the
strategy or might not be willing to implement the
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show that not all healthcare workers have been exposed to the
national TB treatment guidelines and many are not prescribing
recommended regimens [10–12].
In intermediate-to-low TB incidence settings, a further challenge
is that healthcare workers, due to the few cases of TB presenting,
might not be aware of the global guidelines on TB treatment and,
thus, do not follow these. The European Union (EU) is a
heterogeneous setting, with countries and settings ranging from
low- to high-TB incidence [13]. The challenge in low-incidence
settings is to maintain the knowledge of TB and, thus, awareness
of treatment regimens and guidelines.
To assess the future risk of new compounds being used in
inappropriate TB regimens, we conducted a systematic review to
assess the prevalence of inappropriate TB drug prescriptions
(type, dose, frequency of dosing and combination) for the
treatment of TB. Appropriate treatment was defined according
to the WHO guidelines.
METHODS
Search strategy
Toidentifyrelevantstudiesweconducted aliteraturesearch inthe
bibliographic databases MEDLINE and EMBASE in January 2011.
We searched for guidelines in the National Guideline Clearing-
house, the National Institute of Health and Clinical Excellence
(NICE) and the Scottish Intercollegiate Guidelines Network
(SIGN) databases. Abstracts of conference proceedings were
searched in BIOSIS. Reviews and guidelines were searched for in
the TRIP database. Keywords used in the search were determined
in collaboration with the clinical librarian of the Dutch Cochrane
Centre (Amsterdam, the Netherlands) and included
‘‘Tuberculosis’’ OR ‘‘TB’’ OR ‘‘Mycobacterium’’ AND, for TB
treatment, ‘‘Prescriptions’’ OR ‘‘Treatment regimen’’ OR ‘‘Com-
bination treatment’’ OR ‘‘Treatment strategy/-ies’’ OR ‘‘Drug
supply’’ OR ‘‘Standard treatment/standard regimen’’ OR ‘‘Inapp-
ropriate use, appropriate use, rational use, irrational use, misuse’’.
The search was limited to publication years 2000–2010 as we were
interested in recent prescription behaviour. We excluded case
reports. The search strategy was supplemented by hand searching
reference lists of identified articles and relevant review articles.
Selection of studies
We included observational studies investigating the prescrip-
tion of TB treatment regimens in a TB patient population; these
can include cross-sectional studies and cohort studies, both
prospective and retrospective. Only studies in which treatment
regimen was measured as an outcome were included.
Therefore, we excluded studies in which prescription of a
treatment regimen was only described in the methods section.
Furthermore, we excluded studies that provided information
about the prescribed drugs but not about the prescribed
treatment regimens, and studies that did not report the
treatment regimens in sufficient detail to make a judgment
on the appropriateness of the regimen. This also included
studies with multidrug-resistant TB patients that reported
providing individualised treatment and did report the indivi-
dual drug resistance patterns.
We searched publications from the year 2000 onwards. Papers
with data collection starting before 1995 were excluded
because the first WHO treatment guidelines were published
in 1993. Assuming a 2-yr implementation period, these
guidelines would only be expected to be followed from 1995
onwards. There was no language restriction.
Studies identified by the search strategy were reviewed for
eligibility based on title and abstract by one investigator (M.J.
van der Werf). Full manuscripts of the records kept based on
title/abstract were assessed by one investigator (M.J. van der
Werf). For both steps a 10% random sample was assessed by
a second investigator (M.W. Langendam) and compared
with the assessment of the first reviewer. Inconsistencies in
assessment were discussed and disagreements resolved by
consensus. A complete double selection was planned if the
10% random sample revealed relevant inconsistencies.
Data extraction
One reviewer (M.W. Langendam) extracted all relevant data
items from the included studies using a data extraction form. A
second reviewer (M.J. van der Werf) independently extracted
the main results of the included studies and checked the other
extracted results for a subsample of the articles. Inconsistencies
were discussed to obtain consensus.
Data analysis and synthesis of results
The results were summarised qualitatively. For studies that
described treatment regimens without indicating whether they
were appropriate according to the WHO guidelines, the regimen
was assessed and assigned to the appropriate or inappropriate
category using the WHO guidelines as a reference. Table 1
presents the applicable WHO guidelines for different periods of
data collection in the individual studies. In the first and third
editions of the WHO-TB treatment guidelines (1993 and 2003,
respectively) there were specific treatment guidelinesfor children.
In the second edition in 1997, there were no specific guidelines for
c h i l d r e n .W ea l s on o t e di ft h ea u t h o r so ft h em a n u s c r i p t s
considered the regimens to be appropriate or inappropriate. If
t h ed a t aa l l o w e d ,w ea s s e s s e dt h ea d e q u a c yo fd o s i n gf r e q u e n c y ,
dosage and duration of TB treatment. We aimed to assess the
prevalence of inappropriate TB regimen prescription for different
patient populations and different geographical areas.
The quality of reporting of study characteristics and treatment
regimens was assessed using a quality checklist developed for
this review based on the STROBE statement (www.strobe-
statement.org/index.php?id5strobe-home) (table 2).
RESULTS
Study selection
The search in MEDLINE and EMBASE resulted in 1,896 unique
records. A total of 292 papers were considered potentially
TABLE 1 World Health Organization (WHO) guidelines for
periods of data collection
Period of data collection WHO guidelines [Ref.]
1995–1999 First edition: 1993 [6]
1999–2004 Second edition: 1997 [7]
2005–2010 Third edition: 2003 [8]
M.W. LANGENDAM ET AL. SERIES: RATIONAL USE OF ANTI-TUBERCULOSIS DRUGS
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 4 1013relevant based on title/abstract assessment (fig. 1). After full-
text assessment, 37 papers fulfilled the inclusion criteria.
BIOSIS did not provide any additional records. Checking the
reference lists of the included papers revealed no additional
papers that fulfilled the inclusion criteria. The National
Guideline Clearinghouse, NICE, SIGN and TRIP databases
did not provide aggregated evidence on the prevalence of
inappropriate use of TB regimens.
Description of the included studies
37 papers were included. Of these, 26 studies investigated
treatment prescription in the general population (including
three studies in children) and 11 studies were in special groups
(four in extra-pulmonary TB, one in patients with isoniazid-
resistant TB and six in special patient groups).
The 37 papers were from 22 countries, and one study was from
multiple countries (this study is presented in both tables 3 and
4). Almost all continents were represented: Africa (n56), South
America (n52), Europe (n59) and Asia (n520).
The included studies did not provide sufficient information to
assess adequacy of dosing frequency, dose and duration of TB
treatment.
General population including children
Of the 26 studies performed in the general population, 13
(50%) were performed in a hospital setting, 12 (46%) were
based on TB registers and one study was performed in
hospitals, a prison and welfare centres (tables 3–5). The sample
sizes ranged between 32 and 24,760 TB patients.
14 studies had low-quality treatment regimen reporting and 10
of these also had low-quality reporting of the study and
population characteristics. For the treatment regimens, this
means that theregimens were notspecified or that thedescribed
regimens were applied to an undefined mix of patients (new
and re-treatment cases, pulmonary TB and extra-pulmonary TB
cases, and/or smear-negative and-positive cases), in which case
it was not possible to categorise the treatment as appropriate or
inappropriate. According to the author statements in these
14 studies, in two studies, all patients received appropriate
TABLE 2 Quality of reporting checklist
Quality level Assessment
Setting and population
High quality (***) Adequate description of
Population demographics: at least age and sex
Population TB: new/re-treatment, type of TB and smear positive/negative
Setting: where did the patients come from, e.g. private or public hospital, evaluation of TB control programme
Time period of data collection
Sample size
TB diagnosis
Moderate quality (**) Adequate description of population, setting, time period of data collection and sample size, but no information on TB diagnosis
Low quality (*) No information on population, setting, time period of data collection and sample size
TB treatment regimens
High (***) All observed treatment regimens are reported, separately for new and re-treatment cases, for PTB and EPTB and
smear-positive and smear-negative cases
Moderate (**) Treatment regimens are partly or fully specified, but information is missing. Assumptions are necessary for assessment of
inappropriateness and/or assessment is imprecise (e.g. .10%)
Low quality (*) Treatment regimens are not specified in sufficient detail, but authors make a statement
TB: tuberculosis; PTB: pulmonary TB; EPTB: extra-pulmonary TB.
Identified from MEDLINE,
EMBASE and other databases
(1896 records)
1604 records excluded based on title
and abstract:
  830 not about TB
  84 about latent TB
  473 no observational study
  185 no treatment
  32 health worker prescription preference
255 records excluded based on 
evaluation of full manuscript:
  30 study design
  69 treatment only described in methods
  125 treatment regimen not reported
  20 start data collection before 1995
  8 individualised treatment in MDR-TB
  patients
  3 full text not available
Records retained for review
of full manuscript: n=292
Records included: n=37
FIGURE 1. Summary of literature search and study selection. TB: tuberculosis;
MDR: multidrug resistant.
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1016 VOLUME 39 NUMBER 4 EUROPEAN RESPIRATORY JOURNALregimens [16, 25]. In eight studies, inappropriate regimens had
been prescribed according to the authors; the percentage of
patients on inappropriate regimens ranged from 0.4% to 45%
[14, 17, 29, 30, 35–38]. For two studies we determined the
prevalence of inappropriate treatment; this was 26% in the
study from India and o10% in the study with children in Benin
[15, 34]. Two studies did not provide information on treatment
regimens but reported on inadequate numbers of tablets and/or
inadequate dosage [24, 33].
Six studies provided moderate quality information on the
observed treatment regimens [18, 21–23, 26, 27]. In all six
studies, the prevalence of inappropriate treatment regimens
could be calculated from the different treatment regimens or
derived from a table in the paper, under the assumption that
all cases were smear-positive cases (this could not be derived
from the papers). For smear-negative cases, a non-isoniazid,
rifampicin, pyrazinamide, ethambutol (HRZE) regimen might
be appropriate, in which case the prevalence of inappropriate
treatment would be overestimated in our calculations [8]. The
percentage of prescription of inappropriate TB treatment
regimens ranged between 7% and 100%.
For six studies, high-quality information on the observed
treatment regimens was available [19, 20, 28, 31, 32, 39]. In one
study, among new TB cases, inappropriate regimens were
prescribed to 26% of smear-positive pulmonary TB patients,
4% of smear-negative pulmonary TB cases and 29% of extra-
pulmonary TB cases [39]. In the study of SATYANARAYANA et al.
[28], ,0.5% received a regimen without rifampicin and thus
received inappropriate treatment. There was no inappropriate
treatment regimen prescription in the other studies.
Special groups
Of the 11 studies in special groups, four studies were
performed in TB patients with extra-pulmonary TB (table 6)
[40–43]. The WHO recommends Category 1 treatment (HRZE
or HRZ plus streptomycin (S)) for new cases with severe forms
of extra-pulmonary TB and Category 3 treatment for less
severe forms (HRZ in 1993 and 1997, HRZE in 2003) [6–8]. In
two studies, all patients were treated as recommended by the
WHO; these studies had very small sample sizes [41, 42]. In the
other two studies, the percentage of inappropriate treatment
was 5% and 18%, respectively [40, 43].
One study investigated TB treatment of isoniazid-resistant
patients in 2001–2005 [44]. The WHO had no recommendations
on appropriate treatment for isoniazid-resistant patients until
2009; therefore, we could not assess the percentage of patients
with inappropriate treatment.
Six studies reported on special populations such as pregnant
females or AIDS patients. All studies had relatively small
sample sizes; between nine and 52 TB patients. Two studies
provided sufficient information (0% received inappropriate
treatment)[45,46],inanother twostudies 33% and67%received
inappropriate treatment, respectively [47, 48], and in a further
two studies insufficient information was provided [49, 50].
DISCUSSION
In this article we assessed the prevalence of inappropriate
prescription of TB drugs (type, dose, frequency of dosing and
combination) for treatment of TB. Appropriate treatment was
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EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 4 1017defined according to the WHO guidelines. In total, 37 studies
on TB treatment regimens were included. Only eight of these
studies (six in the general population and two in special
groups) reported all information that was necessary to make an
adequate assessment of the prevalence of the inappropriate
treatment prescription. The main challenge with the data
reporting was that the treatment regimens were often not
provided separately for new and re-treatment cases, smear-
positive and smear-negative cases, and pulmonary and extra-
pulmonary TB (e.g. studies stated ‘‘all patients started
on HRZE’’). These patient characteristics are important to
consider as the WHO recommends different treatment regi-
mens for each of these categories.
We adopted a broad search and selection strategy to include as
many studies as possible with data on prescription of TB
treatment regimens. For 13 (35%) out of the 37 included studies,
evaluation of the prescribed treatment was one of the objectives
(i.e. being specifically mentioned in the objective or aim of the
study) [15, 16, 18, 24, 28, 29, 31, 32, 34, 35, 38, 39, 44]. One would
expect that these studies score ‘‘moderate’’ or ‘‘high’’ quality on
treatmentregimenreporting,butthiswasonlythecaseforsixout
of the 12 studies.
In 67% of the studies, inappropriate treatment regimens were
prescribed and the percentage of patients on inappropriate
treatment regimens varied widely between 0.4% and 100%. The
data suggest that the prevalence of inappropriate treatment was
lower in the more recent years. These findings have to be
interpretedwith caution,however,astheprevalencecouldoften
only be estimated and the quality of reporting was low.
It appears that many of the included studies are from settings
that are, or should be, informed on WHO treatment guidelines.
Few studies are from private healthcare settings and none of
the studies examined patients of individual private doctors.
These are two groups of healthcare workers in which
familiarity with international TB guidelines might be lower
and thus have a higher level of inappropriate treatment
prescription. Studies examining what TB treatment regimens
private practitioners would prescribe show that often national
or international guidelines are not often followed [51–53].
Three studies were based in EU Member States with
intermediate-to-low TB incidence (France, Germany and Spain)
[36–38] and in all three studies, inappropriate treatment of cases
was reported. Although the number of studies is limited and the
quality of reporting ranged from low to high, these findings show
inappropriateTB treatment isprescribedthat in the EU. Asstated
in the European action plan to fight TB in the EU [54] and the
follow-up of the action plan [55], it is essential that all TB patients
be diagnosed and provided optimal TB treatment; without such
efforts, TB transmission cannot be prevented and TB elimination
achieved. Furthermore, the risk for resistance development
remains. Regardless of TB incidence in a given setting, providing
accurate treatment is essential to prevent transmission as well as
prevent development of drug resistance.
In 17 (46%) out of the 37 included studies, the definition of TB
diagnosis was not specified. Inspection of the data revealed
that the availability of a TB case definition was not related
to the quality of reporting of the treatment regimens or
prevalence of inappropriate treatment regimens.
10 (27%) studies had a data collection period that included two
or more WHO guideline periods, for example 1993 and 1997.
There are differences between the guidelines, the most
important being the inclusion of streptomycin in Category 1
treatment. In 1993 and 1997 this was recommended in the
guidelines, but not in 2003. In these cases, we considered both
HRZE and HRZS as appropriate treatment.
TB treatment consists of different treatment modalities: regi-
men, dose, frequency and duration. Other important aspects
that are necessary for a successful treatment outcome are
treatment compliance and quality of the drugs. The WHO
guidelines recommend treatment regimens with an intensive
and continuation phase (e.g. HRZE for intensive phase and HR
for continuation) and with a certain frequency (3 days per week
or daily), duration (e.g. 6 months) and dosage (e.g. 4–6 mg?kg
-1
INH daily). In this article we could only assess treatment
regimen as there was insufficient information on dose,
frequency and duration of treatment.
Defining any regimen that is in line with WHO Guidelines as
‘‘appropriate’’ and all others as inappropriate is a rough
distinction between right and wrong. Treatment against TB
may be inappropriate because: 1) the treatment duration is too
short or the regimen contains too few drugs, has insufficient
dose or drugs in a wrong combination; or 2) the duration of
treatment is too long, with an excessive dose or number of
drugs. The first error may cause drug resistance, while the
second error increases the risk of side-effects and conse-
quently low-treatment compliance and, thus, increased treat-
ment failure. Unfortunately, in most included studies the
treatment regimens were not reported in sufficient detail to
make a distinction between these two forms of inappropriate
treatment.
Conclusion
Despite the fact that assessment of the prevalence of
inappropriate TB treatment regimens was hampered by low
quality of reporting, our data indicate a reasonable amount of
inappropriate prescription of TB treatment regimens, as this
was observed in the majority of the included studies. Thus,
there is a risk that new drugs will be used in inappropriate
treatment regimens, even with official WHO guidelines in
place, introducing the subsequent risk of resistance develop-
ment to these new drugs. This article highlights the need to
ensure optimal implementation of the WHO treatment of TB
guidelines in all settings.
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